But Jack is really excited and pleased with what Eisai is doing and has done. They are looking forwaed to the great things to come.
The drug did not perform as expected or wished for. Not sure they are moving forward with phase 3 until a phase 2 gives them what they want.
I agree Eisai will be forced to make a decision. Hope they make the right one.
Eisai Co.’s shares dropped the most in more than six years after partner Biogen Idec Inc.’s experimental Alzheimer’s drug failed to show a statistically significant cognitive benefit for patients on a key dose.
The Japanese drugmaker’s shares traded 8.2 percent lower at 8,114 yen at 9:57 a.m. in Tokyo today, the biggest decline on an intraday basis since October 2008.
The findings, in data released Wednesday, left unresolved questions about the appropriate dosage for the drug called BIIB037, even as Biogen moves into the next phase of trials. Eisai has an option to co-develop and co-promote BIIB037 with Biogen.
Earlier data had pointed to the drug giving a better response at higher doses, though it also showed harsher side effects. The new results didn’t provide clear direction on whether a dose somewhere in the middle would be the answer.
At a dose of 6 milligrams per kilogram, patients on BIIB037 had a cognitive decline of 1.96 points on the Mini Mental State Examination scale, compared with 2.81 for people on a placebo -- suggesting cognitive decline was slower on the drug, though not enough to be statistically significant.
Thanks for all the replies,
Crazy that 2 days after this announcement we are down so much not that I thought we should bounce a buck or so but should have at least held and moved up a little.... Good news takes us down, bad news takes us down, no news takes us down.
In 12 weeks we will have enough data to show our drug is worth anything. Proof of concept.
I did not know they had announced a 52 week study yet. As far as I know this is the only clinical study going on for APD334.
why are we just doing a 12 week Phase 2 for ulcerative colitis a bigger pool of diseases can be addressed and should be addressed... Maybe UCLA MD can shed some light on this strategy.
Your deal you are hoping for faded away a while ago. Eisai wants to much and they are not letting go.
Heck cut Cindy, not sure what she really does, well maybe I am. She manages the Eisai relationship from Switzerland. Isn't prostitution legal in Switzerland?
Your big Tuesday news is now 2 Tuesdays late.... Guess that prediction was not very accurate.
New ID, why do you try and clone someone else on here? Do you really feel so inadequate that you can not stand on your own id? Sad.
Secondly, many independent third party studies prove your statement wrong. Belviq is the safest weight loss drug on the market today..... and the truth shall set you free John 8:32